Stock Scorecard
Stock Summary for Zura Bio Ltd - Class A (ZURA) - $5.38 as of 7/28/2026 3:52:29 PM EST
Total Score
10 out of 30
Safety Score
27 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ZURA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ZURA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ZURA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ZURA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ZURA (27 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ZURA
Financial Details for ZURA
Company Overview |
|
|---|---|
| Ticker | ZURA |
| Company Name | Zura Bio Ltd - Class A |
| Country | USA |
| Description | Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing breakthrough therapies for autoimmune disorders and rare diseases. The company features a diverse pipeline of drug candidates, underpinned by rigorous research methodologies and clinical trials that validate their efficacy and safety profiles. With a leadership team experienced in biopharmaceuticals and strong strategic partnerships, Zura Bio is well-positioned to capitalize on growth opportunities in the sector, making it an attractive investment prospect for institutional investors seeking exposure to innovative therapeutic solutions. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | 8/13/2026 |
Stock Price History |
|
| Last Day Price | 5.38 |
| Price 4 Years Ago | 10.21 |
| Last Day Price Updated | 7/28/2026 3:52:29 PM EST |
| Last Day Volume | 384,617 |
| Average Daily Volume | 1,323,758 |
| 52-Week High | 7.44 |
| 52-Week Low | 1.34 |
| Last Price to 52 Week Low | 301.49% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 32.70 |
| Sector PE | 74.29 |
| 5-Year Average PE | 0.70 |
| Free Cash Flow Ratio | 2.26 |
| Industry Free Cash Flow Ratio | 36.09 |
| Sector Free Cash Flow Ratio | 35.36 |
| Current Ratio Most Recent Quarter | 19.33 |
| Total Cash Per Share | 2.38 |
| Book Value Per Share Most Recent Quarter | 2.28 |
| Price to Book Ratio | 2.29 |
| Industry Price to Book Ratio | 13.89 |
| Sector Price to Book Ratio | 9.14 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 8.80 |
| Sector Price to Sales Ratio Twelve Trailing Months | 31.35 |
| Analyst Buy Ratings | 6 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 94,881,000 |
| Market Capitalization | 510,459,780 |
| Institutional Ownership | 79.07% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -31.00% |
| Reported EPS 12 Trailing Months | -1.09 |
| Reported EPS Past Year | -0.22 |
| Reported EPS Prior Year | -1.06 |
| Net Income Twelve Trailing Months | -75,431,000 |
| Net Income Past Year | -68,650,000 |
| Net Income Prior Year | -52,403,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 225,594,000 |
| Total Cash Past Year | 109,407,000 |
| Total Cash Prior Year | 176,498,000 |
| Net Cash Position Most Recent Quarter | 225,594,000 |
| Net Cash Position Past Year | 101,651,000 |
| Long Term Debt Past Year | 7,756,000 |
| Long Term Debt Prior Year | 7,756,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.93 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 101,538,000 |
| Total Stockholder Equity Prior Year | 146,815,000 |
| Total Stockholder Equity Most Recent Quarter | 216,896,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -72,751,999 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.77 |
| Free Cash Flow Past Year | -64,928,000 |
| Free Cash Flow Prior Year | -28,151,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.25 |
| MACD Signal | 0.25 |
| 20-Day Bollinger Lower Band | 3.50 |
| 20-Day Bollinger Middle Band | 5.05 |
| 20-Day Bollinger Upper Band | 6.61 |
| Beta | -0.04 |
| RSI | 54.36 |
| 50-Day SMA | 4.46 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 7/28/2026 12:00:14 PM EST |